FDA gives long awaited green light to veterans cannabis trial for PTSD
The FDA is permitting a large cohort of American veterans to smoke medical cannabis in a study aimed at gaining insights for combatting PTSD. The Multidisciplinary Association for Psychedelic Studies (MAPS) has been pushing for this since 2021.
The Multidisciplinary Association for Psychedelic Studies, or MAPS, announced… that the U.S. Food and Drug Administration (FDA) granted approval for Phase 2 of the research… “a randomized, placebo-controlled study of 320 Veterans suffering from moderate to severe PTSD who have previously used cannabis.” The group said the study “is designed to investigate the inhalation of high THC dried cannabis flower, versus placebo cannabis, with the daily dose being self-titrated by participants.” It’s meant to reflect consumption patterns already happening across the country and study “the ‘real-world’ use of inhaled cannabis to understand its potential benefits and risks in treating PTSD.” Allison Coker, director of cannabis research at MAPS, said the resolution with FDA came when the agency said it would allow Phase 2 to proceed with smoked cannabis at commercially available THC levels.
Original Article (Mugglehead & Marijuana Moment):
FDA gives long awaited green light to veterans cannabis trial for PTSD & FDA approves long-awaited clinical trial of smoked marijuana to treat PTSD in veterans
Artwork Fair Use: Mkf pm801
Recent Comments